DiaMedica Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 11 - Net Loss Per Share (Tables)

Note 11 - Net Loss Per Share (Tables)

3 Months Ended

Mar. 31, 2022

Notes Tables

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

		Three Months Ended March 31,
		2022				2021
Net loss		$	(3,508	)		$	(3,622	)
Weighted average shares outstanding—basic and diluted			26,443,067				18,766,656
Basic and diluted net loss per share		$	(0.13	)		$	(0.19	)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

		Three Months Ended March 31,
		2022				2021
Employee and non-employee stock options			2,159,413				1,421,094
Common shares issuable under common share purchase warrants			265,000				265,000
Common shares issuable under deferred stock units			134,402				72,142